PharmaCyte BiotechPMCB -0.30%32 Current Ratio is 12.33 as of Jan. 2026, which is 147% above its 10-year median of 5.00. GuruFocus rates PMCB with a GF Score™ of 32/100. The stock has 2 warning signs investors should review. Among 1,416 Biotechnology companies, PharmaCyte Biotech ranks better than 82.63% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. PharmaCyte Biotech's current ratio for the quarter that ended in Jan. 2026 was 12.33.
PharmaCyte Biotech has a current ratio of 12.33. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for PharmaCyte Biotech's Current Ratio or its related term are showing as below:
PMCB'
s Current Ratio Range Over the Past 10 Years
Min: 0.21 Med: 5 Max: 468.71
Current: 12.33
During the past 13 years, PharmaCyte Biotech's highest Current Ratio was 468.71. The lowest was 0.21. And the median was 5.00.
PMCB's Current Ratio is ranked better than 82.63% of 1416
companies
in the Biotechnology industry
Industry Median: 3.885
vs PMCB: 12.33
PharmaCyte Biotech (NAS:PMCB) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
PharmaCyte Biotech Current Ratio Related Terms
PharmaCyte Biotech Current Ratio Historical Data
* Premium members only.
The historical data trend for PharmaCyte Biotech's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PMCB vs IMNN, ACXP, ENVB: Current Ratio Comparison
For the Biotechnology subindustry, PharmaCyte Biotech's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PharmaCyte Biotech Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PharmaCyte Biotech's Current Ratio distribution charts can be found below:
* The bar in red indicates where PharmaCyte Biotech's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PharmaCyte Biotech (PMCB) has a Current Ratio of 12.33 as of Jan. 2026. This is 147% above median its historical median of 5.00. Over the past decade, PharmaCyte Biotech's Current Ratio has ranged from 0.21 to 468.71. According to the industry distribution chart, PharmaCyte Biotech ranks #246 out of 1416 companies in the Biotechnology industry, placing it in the top 17.4%.
Is PharmaCyte Biotech's Current Ratio too high?
PharmaCyte Biotech's current Current Ratio of 12.33 is 147% above median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 0.21 to a high of 468.71. The Biotechnology industry median Current Ratio is 3.89. PharmaCyte Biotech's value of 12.33 is 217.4% above this industry median. Based on the distribution chart, PharmaCyte Biotech ranks #246 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, PharmaCyte Biotech has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does PharmaCyte Biotech's Current Ratio compare to IMNN and ACXP?
According to the Biotechnology industry distribution chart, PharmaCyte Biotech ranks #246 out of 1416 companies for Current Ratio. This places PharmaCyte Biotech in the top 17% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.89. PharmaCyte Biotech's value of 12.33 is 217.4% above this benchmark. Historically, PharmaCyte Biotech's own Current Ratio has ranged from 0.21 to 468.71 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 3.89, PharmaCyte Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PharmaCyte Biotech's current Current Ratio of 12.33 is 217.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PharmaCyte Biotech's current Current Ratio is 12.33, which is 147% above median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCyte Biotech stock overvalued right now?
PharmaCyte Biotech (PMCB) has a current Current Ratio of 12.33. The current Current Ratio is 12.33, which is 147% above median its 10-year median of 5.00 and 217.4% above the Biotechnology industry median of 3.89. PharmaCyte Biotech's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For PharmaCyte Biotech (PMCB), the current Current Ratio is 12.33 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
32GF Score
Get the complete analysis for PMCB
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PMCB has been successfully added to your 
